If Joe Hockey & Bondi Partners couldn't get something happening in the US at the height of the Covid opportunities, it ain't happening now.
Atomo don't have distribution rights for the AccessBio CareStart antigen test in the US. Therefore, the only "Access Bio connection in this exercise" would be for the antibody tests, which is a dead market at the moment.
Glad I sold the majority of my holdings before it dipped below 30c. I'm still holding some in hopes that something exciting might materialise, but at this point, I don't even think TGA approval for the self-test will be that significant (late to market, likely higher costs, lower accuracy, swab test rather than saliva).
AT1 Price at posting:
21.0¢ Sentiment: Hold Disclosure: Held
